Vitafarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 28,283,664 | 27,086,097 | 25,883,717 | 18,526,843 | 17,954,206 | 14,583,504 | 19,197,376 | 20,624,849 |
| Profit before tax | 1,080,970 | 658,609 | 329,163 | 214,359 | 95,312 | 339,831 | 464,403 | 287,728 |
| Net profit | 923,902 | 562,594 | 321,069 | 175,295 | 71,834 | 284,203 | 377,678 | 232,121 |
| Equity | 1,464,335 | 596,929 | 417,998 | 593,293 | 665,127 | 949,330 | 1,326,744 | 1,558,865 |
| Liabilities | 5,433,289 | 4,240,905 | 2,180,229 | 2,548,730 | 2,510,551 | 3,060,305 | 3,416,510 | 5,070,327 |
| Non-current assets | 443,389 | 527,876 | 391,507 | 287,733 | 143,711 | 77,746 | 975,307 | 947,813 |
| Current assets | 6,472,340 | 4,320,723 | 2,213,917 | 2,833,978 | 3,081,757 | 3,948,177 | 3,777,753 | 5,694,046 |
| Total assets | 6,915,729 | 4,848,599 | 2,605,424 | 3,121,711 | 3,225,468 | 4,025,923 | 4,753,060 | 6,641,859 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 198,793 | 350,663 | 542,703 |
| Social insurance contributions | - | - | - | - | - | 65,053 | 67,596 | 85,513 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +28.8% | -4.2% | -4.4% | -28.4% | -3.1% | -18.8% | +31.6% | +7.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 13.4% | 11.6% | 12.3% | 5.6% | 2.2% | 7.1% | 7.9% | 3.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 63.1% | 94.2% | 76.8% | 29.5% | 10.8% | 29.9% | 28.5% | 14.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.3% | 2.1% | 1.2% | 0.9% | 0.4% | 1.9% | 2.0% | 1.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.8% | 2.4% | 1.3% | 1.2% | 0.5% | 2.3% | 2.4% | 1.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.7 | 7.1 | 5.2 | 4.3 | 3.8 | 3.2 | 2.6 | 3.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,571,242 | 1,969,898 | 1,795,398 | 1,201,739 | 1,146,011 | 1,011,570 | 1,371,241 | 1,556,592 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vitafarma - Social security debts
The company had no debts to Sodra
Vitafarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Vitafarma, UAB (code 135915083) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €20.62M, up 7.4% year on year and 41.4% compared with 2023. Net profit was €232.1K, down from €377.7K in 2024 but still above the €284.2K reported in 2023. The 2025 profit margin was 1.1%, indicating a relatively low but positive level of profitability. Over the three-year period, revenue increased steadily from €14.58M in 2023 to €19.20M in 2024 and €20.62M in 2025, while earnings peaked in 2024 before easing in 2025. The balance sheet expanded from €4.03M in assets in 2023 to €6.64M in 2025, supported by equity of €1.56M and liabilities of €5.07M. Key ratios for 2025 show ROE of 14.9%, ROA of 3.5%, debt-to-equity of 3.25, and asset turnover of 3.11x. Revenue per employee reached €1.59M, with profit per employee of €17.9K.